Latest Conference Articles

March 14th 2019, 11:02pm

PER® Miami Breast Cancer Conference

Blood-based biomarkers offer great potential for use in the management of breast and other cancers.

March 14th 2019, 12:04am

PER® Miami Breast Cancer Conference

David M. Euhus, MD, discusses a new trio of genes entering the risk assessment equation in hereditary breast cancer.

March 13th 2019, 8:43pm

PER® Miami Breast Cancer Conference

Identifying patients with ductal carcinoma in situ who are more likely to develop invasive breast cancer remains a challenge, despite decades of research and the development of stratification methods to predict progression and recurrence.

March 12th 2019, 8:04pm

PER® Miami Breast Cancer Conference

There has been much progress in the treatment of estrogen receptor-positive metastatic breast cancer over the past 40 years, and novel therapies are further expanding therapeutic options.

March 12th 2019, 6:48pm

PER® Miami Breast Cancer Conference

CtDNA will continue to gain importance in precision oncology as physicians continue to uncover the role and interplay of genomic alterations that promote tumor heterogeneity.

March 10th 2019, 3:21am

PER® Miami Breast Cancer Conference

Although the first checkpoint inhibitor has just been approved for patients with breast cancer, findings from dozens of ongoing studies may eventually change the paradigm for large subsets of those with the malignancy.

March 10th 2019, 2:56am

PER® Miami Breast Cancer Conference

The development of antibody-drug conjugates represents a promising strategy for patients with metastatic triple-negative breast cancer, with early clinical trial results suggesting that novel agents could eventually change the landscape for this patient population.

March 10th 2019, 2:45am

PER® Miami Breast Cancer Conference

With tremendous advances and the accelerated approval of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer, provider education in identifying associated toxicities from checkpoint inhibitor therapy is critical.

March 10th 2019, 1:23am

PER® Miami Breast Cancer Conference

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Comprehensive Cancer Center, discusses the therapeutic advancements in the breast cancer space in the past 20 years.

March 9th 2019, 7:27pm

PER® Miami Breast Cancer Conference

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies being investigated with CDK4/6 inhibitors in breast cancer.

March 9th 2019, 2:44am

PER® Miami Breast Cancer Conference

The introduction of PARP inhibitors into the breast cancer treatment paradigm is a clinically meaningful advance for patients with germline BRCA1/2 mutations but much more research must be conducted to optimize their use.

March 9th 2019, 2:35am

PER® Miami Breast Cancer Conference

The previously demonstrated progression-free survival benefit from the addition of alpelisib to fulvestrant appeared consistent among subgroups of patients with hormone receptor–positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.

March 9th 2019, 1:55am

PER® Miami Breast Cancer Conference

For more than 100 years, endocrine therapy has been used for the treatment of breast cancer; since that time, we have learned much about the role of estrogen in the biology of normal breast cancer development.

March 9th 2019, 1:44am

PER® Miami Breast Cancer Conference

Each gene expression-based test available for risk prediction in patients with breast cancer has unique properties and they are not interchangeable, placing importance on the clinical studies used to validate the clinical utility of each assay.

March 9th 2019, 1:27am

PER® Miami Breast Cancer Conference

Elizabeth A. Mittendorf, MD, PhD, director of the Breast Immuno-Oncology Program at Dana-Farber/Brigham and Women's Cancer Center, discusses the frontline approval of atezolizumab in combination with nab-paclitaxel in patients with locally advanced or metastatic PD-L1

March 9th 2019, 12:47am

PER® Miami Breast Cancer Conference

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the recent FDA approval of subcutaneous use of trastuzumab (Herceptin) and hyaluronidase-oysk injection (Herceptin Hylecta) in the HER2-positive breast cancer space.

March 8th 2019, 9:55pm

PER® Miami Breast Cancer Conference

After nearly 30 years as a breast cancer surgeon, Patrick I. Borgen, MD, finds that the most enduring theme in the field is constant change.

March 8th 2019, 9:30pm

PER® Miami Breast Cancer Conference

The breast cancer field is experiencing rapid advancements in the understanding of disease biology and the development of novel therapeutic strategies for several subtypes, with a clear direction toward personalized or precision medicine.

March 8th 2019, 8:51pm

PER® Miami Breast Cancer Conference

Data from the SHAVE and SHAVE2 trials, in terms of long-term outcomes vis-à-vis local recurrence, may lend some insight into the impact of adjuvant therapy on reducing the ramifications of a positive margin.

March 4th 2019, 4:40am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Morie A. Gertz, MD, MACP, discusses the current outlook for patients with Waldenström macroglobulinemia.